Psychemedics Corporation (PMD)


-0.16 (-2.52%)
Symbol PMD
Price $6.18
Beta 0.695
Volume Avg. 0.01M
Market Cap 34.770M
Shares () -
52 Week Range 6.01-8.9
1y Target Est -
DCF Unlevered PMD DCF ->
DCF Levered PMD LDCF ->
ROE -5.47% Neutral
ROA -3.38% Neutral
Operating Margin -
Debt / Equity 68.27% Buy
P/E -
P/B 2.77 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest PMD news

Mr. Raymond Kubacki
Diagnostics & Research
NASDAQ Capital Market

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.